D. Boral Capital analyst Jason Kolbert upgraded Plus Therapeutics (PSTV) to Buy from Hold with a $5 price target The firm, which previously had lowered its rating in May on concerns that the company was likely to execute a reverse split, says it seems those concerns “may have faded” for the moment and also cites the progress the company has been making on the diagnostics side. With catalysts such as a diagnostics launch, the firm sees the stock being back up over the “critical $1.00 mark,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics regains compliance with applicable Nasdaq listing criteria
- Plus Therapeutics Secures Nasdaq Compliance Extension
- Plus Therapeutics price target lowered to $3 from $4 at Maxim
- Plus Therapeutics presents results from ReSPECT-LM Phase 1 trial
- Optimistic Buy Rating for Plus Therapeutics Driven by Strategic Financial Positioning and Clinical Advancements